Barclays Raises PT on Hims & Hers Health (HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 12 Most Shorted Stocks to Buy in 2026. On March 11, Barclays analyst Glen Santangelo lifted its price objective on the company’s stock to $29 from $25, while keeping an “Overweight” rating. The analyst highlighted that a strong increase in share price after the Novo Nordisk agreement reflects a significant market opportunity.

Barclays Raises PT on Hims & Hers Health (HIMS) Stock

Additionally, it also demonstrates the removal of legal overhang for Hims & Hers Health, Inc. (NYSE:HIMS)’s stock. As per the firm, the broader market has been underappreciating the company’s opportunity from new products.

Notably, in a different release, Hims & Hers Health, Inc. (NYSE:HIMS) announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s. In the US, the company aims to offer GLP-1 customers access to a broad assortment of medications that are FDA-approved, and provide compounded semaglutide via the platform on a limited scale.

Hims & Hers Health, Inc. (NYSE:HIMS) is a consumer-first health and wellness platform, connecting consumers to licensed healthcare professionals.

While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.